• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Regeneron unveils topline Ph3 diabetic retinopathy data for blockbuster eye drug

March 20, 2018 By Sarah Faulkner

Regeneron Pharmaceuticals‘ (NSDQ:REGN) eye drug Eylea brought in nearly $6 billion in sales last year. In an attempt to keep the injectable drug in a league of its own, the biotech plans to apply for a new indication with the FDA this year.

The company today announced results from a Phase III trial evaluating Eylea in patients with non-proliferative diabeteic retinopathy. The study met its primary endpoint after 24 weeks – 58% of patients treated with Eylea had a two-step or greater improvement from baseline on the diabetic retinopathy severity scale compared to just 6% of patients receiving a sham injection.

“This is the first time a therapy has demonstrated it can reverse disease progression in patients with moderately severe to severe non-proliferative diabetic retinopathy without diabetic macular edema, in a trial specifically designed to study this population,” president & chief scientific officer Dr. George Yancopoulos said in prepared remarks. “Patients in the trial continue to be evaluated to determine if Eylea can prevent progression to neovascular vision-threatening complications or diabetic macular edema.”

The company plans to report one-year results from the 402-patient late-stage trial later this year. The results from Regeneron’s Panorama trial will support a supplemental biologics license application, the company reported.

Millions of people live with diabetic retinopathy, according to Regeneron, but the condition starts as non-proliferative diabetic retinopathy. More than half a million people in the U.S. have moderately severe or severe non-proliferative diabetic retinopathy without diabetic macular edema.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Diabetes, Featured, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Regeneron

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS